reports hero background
Updated: Sep 6, 2026
DRTS Logo

Alpha Tau Medical

NASDAQ:DRTS·Stock Analysis Report
Day Range
$14.27 - $14.84
Market Cap
1.40B
P/E Ratio
0.0000
Avg Value
$9.27
Year Range
$3.43 - $15.10
$14.27-$0.57 (-3.84%)
1
General Information
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors.

Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.

2
Alpha Tau Medical (DRTS) Stock Graph
3
How We Grade Alpha Tau Medical (DRTS)

We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health.

The chart below shows how we grade Alpha Tau Medical (DRTS) across the board compared to its closest peers.

4
Benzinga Edge Rankings

Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell.

Momentum measures a stock's relative strength based on its price movement patterns and volatility over multiple timeframes, ranked as a percentile against other stocks.

Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
5
Peer Ratings

See how Alpha Tau Medical compares to its peers in these key performance metrics from Benzinga Rankings.

Top Peers
Value
Quality
Growth
Momentum
Short
Medium
Long
TNDMTandem Diabetes Care
N/A
N/A
N/A
79.15
ATECAlphatec Holdings
N/A
N/A
N/A
7.64
KMTSKestra Medical Techs
N/A
N/A
N/A
82.01
CNMDConmed
33.01
N/A
68.2
69.02
Short: price trend over the last couple of months
Medium: price trend over the last couple of quarters
Long: price trend over the past year
Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
6
Future Growth
Our estimate of future price growth is based on an aggregation of 4 analyst ratings over the past 3 months and their 12-month price targets.

Below, you can see that analysts are estimating a 12-month price target range of $15.00 - $30.00 with an average of $19.00

25.94%
Expected movement for Alpha Tau Medical (DRTS) over the next 12 months
Based on these rankings

Recent Ratings for Alpha Tau Medical (DRTS)

Barclays
Date:
Sep 3, 2026
Action:
Maintains
Prev. Target:
$17.00
New Target:
$30.00
HC Wainwright & Co.
Date:
Aug 11, 2026
Action:
Maintains
Prev. Target:
$15.00
New Target:
$16.00
HC Wainwright & Co.
Date:
Jul 22, 2026
Action:
Reiterates
Prev. Target:
$15.00
New Target:
$15.00
HC Wainwright & Co.
Date:
Jul 16, 2026
Action:
Reiterates
Prev. Target:
$15.00
New Target:
$15.00
7
Past Performance
How has Alpha Tau Medical (DRTS) performed over the past 5 years?

The two main factors that we consider when analyzing past performance is overall return and volatility

Using these two metrics, we can determine if this stock gave its investors enough return for the risk that they took on by owning it. This is measured by the sharpe ratio, which has been used as a primary measure of risk/reward trade-off for almost 60 years.

This ratio can be interpreted as the amount of return an investor has received for the amount of risk that they took on by owning the stock over that timeframe.

Alpha Tau Medical (DRTS) sharpe ratio over the past 5 years is 0.1597 which is considered to be above average compared to the peer average of -0.3935